The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS).
Lisa M. Kopp
No relevant relationships to disclose
Mark L. Bernstein
No relevant relationships to disclose
Cindy L. Schwartz
No relevant relationships to disclose
David Ebb
No relevant relationships to disclose
Mark D. Krailo
No relevant relationships to disclose
Holcombe E. Grier
No relevant relationships to disclose
Paul A. Meyers
No relevant relationships to disclose
Leonard H. Wexler
No relevant relationships to disclose
Neyssa Marina
Honoraria - HONORARIA
Richard Womer
No relevant relationships to disclose
Katherine A. Janeway
No relevant relationships to disclose
Richard Greg Gorlick
Consultant or Advisory Role - Oncolytics Biotech
Stock Ownership - Oncolytics Biotech
Steven E. Lipshultz
No relevant relationships to disclose